文献速递消化道肿瘤与早癌

氯吡格雷与低剂量阿司匹林单用或联用均可降低结直肠癌风险

Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-12-20

西班牙一项基于初级保健数据库的巢式病例对照研究纳入15,491例结直肠癌病例和60,000名对照,评估抗血小板药与结直肠癌风险的关系。低剂量阿司匹林、氯吡格雷单用及双联治疗均与结直肠癌风险降低相关,联用效果与单药相似,未观察到性别或年龄修饰作用。

要点

  • 低剂量阿司匹林与结直肠癌风险降低相关(AOR 0.83,95%CI 0.78-0.89)。
  • 氯吡格雷与结直肠癌风险降低相关(AOR 0.80,95%CI 0.69-0.93)。
  • 双联抗血小板治疗的效果与任一单药治疗相同。

核心结论

  • 在西班牙初级保健数据库的巢式病例对照研究中,氯吡格雷单用或与低剂量阿司匹林联用使结直肠癌风险降低20%至30%,幅度与低剂量阿司匹林单用相似。
  • 这些数据支持抑制血小板是预防结直肠癌的有效策略这一概念。

研究设计与样本

  • 采用西班牙初级保健数据库(Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria)的巢式病例对照研究。
  • 收集2001年至2014年数据,纳入15,491例新发结直肠癌病例和60,000名随机选择的对照,按年龄、性别和年份进行频数匹配。
  • 构建多因素logistic回归模型,计算调整比值比(AOR)及其95%CI,评估不同抗血小板药暴露与结直肠癌风险的关联。

主要发现

  • 低剂量阿司匹林使用与总体结直肠癌风险降低相关(AOR 0.83;95%CI 0.78-0.89),治疗超过1年的患者中AOR为0.79(95%CI 0.73-0.85)。
  • 氯吡格雷使用与总体结直肠癌风险降低相关(AOR 0.80;95%CI 0.69-0.93),治疗超过1年的患者中AOR为0.65(95%CI 0.55-0.78)。
  • 双联抗血小板治疗的效果与任一药物单药治疗相同。
  • 未观察到性别或年龄的修饰作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The antiplatelet effect of low-dose aspirin, via inhibition of cyclooxygenase-1, might contribute to its ability to reduce the risk of colorectal cancer (CRC). Antiplatelet agents with a different mechanism, such as clopidogrel, might have the same effects. We aimed to quantify the effects of low-dose aspirin and clopidogrel on the risk of CRC in a Mediterranean population. METHODS: We performed a nested case-control study using a primary care database (Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria) in Spain. We collected data, from 2001 through 2014, on 15,491 incident cases of CRC and 60,000 randomly selected individuals (controls), frequency-matched to cases by age, sex, and year. To estimate the association between exposure to different antiplatelet agents and the risk of colorectal cancer, we built multiple logistic regression models and computed the adjusted-odds ratios (AORs) and their respective 95% CIs. RESULTS: Use of low-dose aspirin was associated with a reduced risk of CRC overall (AOR, 0.83; 95% CI, 0.78-0.89) and in patients receiving treatment for more than 1 year (AOR, 0.79; 95% CI, 0.73-0.85). Use of clopidogrel was associated with a decreased risk of CRC overall (AOR, 0.8; 95% CI, 0.69-0.93) and in patients receiving treatment for more than 1 year (AOR, 0.65; 95% CI, 0.55-0.78). Dual antiplatelet therapy had the same effect as either drug taken as monotherapy. No modification by sex or age was observed. CONCLUSIONS: In a nested case-control study of a primary care database in Spain, we found clopidogrel use, alone or in combination with low-dose aspirin, to reduce the risk of CRC by 20% to 30%, a magnitude similar to that of low-dose aspirin alone. These data support the concept that inhibiting platelets is an effective strategy for prevention of CRC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Miguel A, García-Rodríguez LA, Gil M, et al. Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer. Clin Gastroenterol Hepatol. 2018. PMID: 30580092. doi:10.1016/j.cgh.2018.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。